Aerovate Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.82 | -$0.82 | -$0.82 |
| Q2 2024 | 3 | -$0.49 | -$0.44 | -$0.47 |
| Q3 2024 | 1 | -$0.40 | -$0.40 | -$0.40 |
| Q1 2025 | 2 | -$0.33 | -$0.33 | -$0.33 |
| Q2 2025 | 2 | -$0.25 | -$0.25 | -$0.25 |
| Q3 2025 | 2 | -$0.18 | -$0.18 | -$0.18 |
| Q4 2025 | 2 | -$0.13 | -$0.13 | -$0.13 |
| Q1 2026 | 1 | -$0.73 | -$0.73 | -$0.73 |
| Q2 2026 | 1 | -$0.55 | -$0.55 | -$0.55 |
| Q3 2026 | 1 | -$0.57 | -$0.57 | -$0.57 |
| Q4 2026 | 1 | -$0.61 | -$0.61 | -$0.61 |
Aerovate Therapeutics, Inc. Earnings Date And Information
Aerovate Therapeutics, Inc. last posted its earnings results on Monday, August 12th, 2024. The company reported $-0.86 earnings per share for the quarter, missing analysts' consensus estimates of $-0.76 by $0.1. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Aerovate Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.87 diluted earnings per share) and currently has a price-to-earnings ratio of -0.87. Aerovate Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 11th, 2024 based on prior year's report dates.
Aerovate Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/12/2024 | Q2 2024 | -$0.76 | -$0.86 | -0.1 | $0 | $0 |
| 05/13/2024 | Q1 2024 | -$0.74 | -$0.83 | -0.09 | $0 | |
| 03/25/2024 | Q4 2023 | -$0.68 | -$0.74 | -0.06 | $136,000 | |
| 11/13/2023 | Q3 2023 | -$0.70 | -$0.71 | -0.01 | $0 | |
| 08/14/2023 | Q2 2023 | -$0.69 | -$0.76 | -0.07 | $0 | |
| 05/15/2023 | Q1 2023 | -$0.58 | -$0.62 | -0.04 | $0 | |
| 03/29/2023 | Q4 2022 | -$0.61 | $0 | |||
| 11/14/2022 | Q3 2022 | -$0.50 | -$0.53 | -0.03 | $0 | |
| 08/15/2022 | Q2 2022 | -$0.46 | -$0.48 | -0.02 | $0 | |
| 05/16/2022 | Q1 2022 | -$0.26 | -$0.44 | -0.18 | $0 | |
| 03/30/2022 | Q4 2021 | -$0.34 | $0 | |||
| 11/15/2021 | Q3 2021 | -$0.26 | -$0.26 | 0 | $0 | |
| 08/16/2021 | Q2 2021 | -$0.16 | -$23.76 | -23.6 | $0 | |
| 03/30/2021 | Q1 2021 | -$0.13 | $0 | |||
| 12/30/2020 | Q4 2020 | -$15.08 | $0 | |||
| 09/29/2020 | Q3 2020 | -$9.49 | $0 | |||
| 06/29/2020 | Q2 2020 | -$9.06 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.32 | $0 |
Aerovate Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Aerovate Therapeutics, Inc.'s earnings date?
Aerovate Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 11th, 2024 based off last year's report dates.
-
How can I listen to Aerovate Therapeutics, Inc.'s earnings conference call?
The conference call for Aerovate Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Aerovate Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Aerovate Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Aerovate Therapeutics, Inc. generate each year?
Aerovate Therapeutics, Inc. (:AVTE) has a recorded net income of $0. Aerovate Therapeutics, Inc. has generated $-2.87 earnings per share over the last four quarters.
-
What is Aerovate Therapeutics, Inc.'s price-to-earnings ratio?
Aerovate Therapeutics, Inc. (:AVTE) has a price-to-earnings ratio of -0.87 and price/earnings-to-growth ratio is 0.27.
